UK Scientists Rush to Develop Ebola Vaccine Amid Congo Outbreak

Ebola Outbreak in the Democratic Republic of Congo

The current Ebola outbreak in the Democratic Republic of Congo (DRC) has resulted in 750 suspected cases and 177 deaths, with the World Health Organization (WHO) upgrading the risk from 'high' to 'very high' in the region. The rare Bundibugyo species of Ebola, for which there is no proven vaccine, kills around a third of those infected.

UK Scientists' Efforts

Scientists at Oxford University are developing a new vaccine that could be ready for clinical trials within two to three months. The vaccine uses the same technology developed during the Covid pandemic, known as ChAdOx1, which can be quickly tweaked to work against different infections. This time, it has been prepared with genetic code from the Bundibugyo species of Ebola.

Historical Context and Regional Implications

There are six species of Ebola virus, but only three cause large outbreaks in people. Bundibugyo has only caused two previous outbreaks - in Uganda in 2007 and DR Congo in 2012 - and has not been seen for over a decade. The lack of a proven vaccine for this species makes the current outbreak particularly challenging.

Future Consequences and Global Response

The WHO has declared a public health emergency of international concern, but stressed that the outbreak is not a pandemic. The risk remains low internationally, but the WHO is urging caution and preparedness. The Serum Institute of India is lined up to mass produce the Ebola vaccine once Oxford can supply medical-grade material.

Strategic Motivations and Public-Interest Significance

The UK scientists' efforts to develop a vaccine against the Bundibugyo species of Ebola demonstrate the importance of preparedness and rapid response in the face of emerging health crises. The use of existing technology and the collaboration with international partners highlight the potential for effective global cooperation in addressing public health threats.

Editor's Note: While the vaccine is expected to be ready for clinical trials within two to three months, there is still uncertainty surrounding its effectiveness.

Source referenced: BBC

This brief was synthesized by our Editorial Engine and reviewed by The Ground Narrative team.